Clostridium difficile bacteria, computer illustration. C. difficile is a normal inhabitant of the human intestine, but it can become a pathogen when antibiotics disrupt the normal intestinal flora and ...

Recurrent C. diff infection is when you contract a C. diff infection 2 to 8 weeks after completing treatment for a previous one. C. diff relapse is a recurrence of the same strain, while reinfection ...

Five insights from the report, written by Clayton Dalton, MD, a resident physician at Boston-based Massachusetts General Hospital: 1. In addition to antibiotic use being a risk factor for C. diff, ...

Some people will get repeat infections from Clostridium difficile (C. diff). They may develop the same symptoms they had before such as diarrhea, stomach pain, and loss of appetite. However, the only ...

FMT restores gut microbiota balance by transferring stool from healthy donors, mainly for recurrent C. difficile infections. Recent data shows FMT's high efficacy in preventing recurrent C. difficile, ...

C. diff colitis is inflammation of a person’s colon due to contagious bacteria. Most people with C. diff colitis fully recover, but in rare cases the condition can be life threatening. It is possible ...

Ferring Pharmaceuticals’ biotherapeutic passed an FDA committee vote despite some skepticism from a handful of members, setting up the asset for potential approval to treat Clostridioides difficile ...

Clostridioides difficile (C. diff) is a stealthy threat. It infects more than 500,000 people in the United States each year, and kills up to 30,000. It is a leading cause of health-care-associated ...

Please provide your email address to receive an email when new articles are posted on . Exposure to a contaminated nearly doubles a patient’s risk for hospital-onset C. difficile infection. This ...

LA Times Studios produces content by working closely with scientists and healthcare experts as well as sourcing scholarly-reviewed medical and science journals and is independent of the L.A. Times ...

Summit Therapeutics believes the future of its lead asset to treat C. difficile may be through partnerships, months after the candidate failed to outperform vancomycin in a phase 3 trial. In an ...

Signs of inflammatory bowel disease (IBD) activity, shorter duration of IBD, and previous corticosteroid use and hospitalisation were associated with Clostridioides difficile infection in patients ...